Close Menu

NEW YORK – UK-based Achilles Therapeutics on Thursday said that it has raised £52.7 million ($69.6M) in a Series C financing round that it will put toward advancing its pipeline of personalized T-cell therapies for solid tumors, including non-small cell lung cancer and melanoma.

OrbiMed, Boxer Capital of Tavistock Group, and others participated in the financing round as new investors. Existing investors, including RA Capital, Syncona, Forbion, Invus, Perceptive Advisors, and Redmile Group, also participated.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.